Cargando…

Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)

BACKGROUND: Hepatitis B is a major concern in Africa, especially in HIV-infected patients. Unfortunately, access to hepatitis B virus (HBV) testing and adequate treatment remains a challenge in the continent. We investigated HBV testing, treatment, and virologic suppression in HIV-infected patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Liégeois, Florian, Boyer, Sylvie, Eymard-Duvernay, Sabrina, Carrieri, Patrizia, Kouanfack, Charles, Domyeum, Jenny, Maradan, Gwenaëlle, Ducos, Jacques, Mpoudi-Ngolé, Eitel, Spire, Bruno, Delaporte, Eric, Kuaban, Christopher, Vidal, Laurent, Laurent, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964089/
https://www.ncbi.nlm.nih.gov/pubmed/31941464
http://dx.doi.org/10.1186/s12879-020-4784-7
_version_ 1783488431613018112
author Liégeois, Florian
Boyer, Sylvie
Eymard-Duvernay, Sabrina
Carrieri, Patrizia
Kouanfack, Charles
Domyeum, Jenny
Maradan, Gwenaëlle
Ducos, Jacques
Mpoudi-Ngolé, Eitel
Spire, Bruno
Delaporte, Eric
Kuaban, Christopher
Vidal, Laurent
Laurent, Christian
author_facet Liégeois, Florian
Boyer, Sylvie
Eymard-Duvernay, Sabrina
Carrieri, Patrizia
Kouanfack, Charles
Domyeum, Jenny
Maradan, Gwenaëlle
Ducos, Jacques
Mpoudi-Ngolé, Eitel
Spire, Bruno
Delaporte, Eric
Kuaban, Christopher
Vidal, Laurent
Laurent, Christian
author_sort Liégeois, Florian
collection PubMed
description BACKGROUND: Hepatitis B is a major concern in Africa, especially in HIV-infected patients. Unfortunately, access to hepatitis B virus (HBV) testing and adequate treatment remains a challenge in the continent. We investigated HBV testing, treatment, and virologic suppression in HIV-infected patients followed up as part of Cameroon’s national antiretroviral programme. METHODS: A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in 19 hospitals in the Centre and Littoral regions in Cameroon. The proportions of patients tested for hepatitis B surface antigen (HBsAg) prior to the study were compared among all study hospitals using the Chi-square test. The association of individual and hospital-related characteristics with HBV testing and virologic suppression was assessed using multilevel logistic regression models. RESULTS: Of 1706 patients (women 74%, median age 42 years, median time on ART 3.9 years), 302 (17.7%) had been tested for HBsAg prior to the study. The proportion of HBV-tested patients ranged from 0.8 to 72.5% according to the individual hospital (p < 0.001). HBV testing was lower in women (adjusted odds ratio [aOR] 0.64, 95% confidence interval [CI] 0.46–0.89, p = 0.010) and higher in patients who initiated ART in 2010 or later (aOR 1.66, 95% CI 1.23–2.27, p < 0.001). Of 159 HBsAg-positive patients at the time of the study (9.3%), only 97 (61.0%) received Tenofovir + Lamivudine (or Emtricitabine). Of 157 coinfected patients, 114 (72.6%) had a HBV viral load < 10 IU/mL. HBV suppression was higher in patients with a HIV viral load < 300 copies/mL (aOR 3.46, 95% CI 1.48–8.09, p = 0.004) and lower in patients with increased ALT level (aOR 0.86 per 10 IU/mL increase, 95% CI 0.75–0.97, p = 0.019). CONCLUSIONS: A substantial proportion of HIV/HBV coinfected patients were at higher risk of liver disease progression. Improving the management of HBV infection in the routine healthcare setting in Africa is urgently required in order to achieve the 2030 elimination targets. Micro-elimination of HBV infection in people living with HIV could be an easier and cost-effective component than more widely scaling up HBV policies.
format Online
Article
Text
id pubmed-6964089
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69640892020-01-22 Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM) Liégeois, Florian Boyer, Sylvie Eymard-Duvernay, Sabrina Carrieri, Patrizia Kouanfack, Charles Domyeum, Jenny Maradan, Gwenaëlle Ducos, Jacques Mpoudi-Ngolé, Eitel Spire, Bruno Delaporte, Eric Kuaban, Christopher Vidal, Laurent Laurent, Christian BMC Infect Dis Research Article BACKGROUND: Hepatitis B is a major concern in Africa, especially in HIV-infected patients. Unfortunately, access to hepatitis B virus (HBV) testing and adequate treatment remains a challenge in the continent. We investigated HBV testing, treatment, and virologic suppression in HIV-infected patients followed up as part of Cameroon’s national antiretroviral programme. METHODS: A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in 19 hospitals in the Centre and Littoral regions in Cameroon. The proportions of patients tested for hepatitis B surface antigen (HBsAg) prior to the study were compared among all study hospitals using the Chi-square test. The association of individual and hospital-related characteristics with HBV testing and virologic suppression was assessed using multilevel logistic regression models. RESULTS: Of 1706 patients (women 74%, median age 42 years, median time on ART 3.9 years), 302 (17.7%) had been tested for HBsAg prior to the study. The proportion of HBV-tested patients ranged from 0.8 to 72.5% according to the individual hospital (p < 0.001). HBV testing was lower in women (adjusted odds ratio [aOR] 0.64, 95% confidence interval [CI] 0.46–0.89, p = 0.010) and higher in patients who initiated ART in 2010 or later (aOR 1.66, 95% CI 1.23–2.27, p < 0.001). Of 159 HBsAg-positive patients at the time of the study (9.3%), only 97 (61.0%) received Tenofovir + Lamivudine (or Emtricitabine). Of 157 coinfected patients, 114 (72.6%) had a HBV viral load < 10 IU/mL. HBV suppression was higher in patients with a HIV viral load < 300 copies/mL (aOR 3.46, 95% CI 1.48–8.09, p = 0.004) and lower in patients with increased ALT level (aOR 0.86 per 10 IU/mL increase, 95% CI 0.75–0.97, p = 0.019). CONCLUSIONS: A substantial proportion of HIV/HBV coinfected patients were at higher risk of liver disease progression. Improving the management of HBV infection in the routine healthcare setting in Africa is urgently required in order to achieve the 2030 elimination targets. Micro-elimination of HBV infection in people living with HIV could be an easier and cost-effective component than more widely scaling up HBV policies. BioMed Central 2020-01-15 /pmc/articles/PMC6964089/ /pubmed/31941464 http://dx.doi.org/10.1186/s12879-020-4784-7 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Liégeois, Florian
Boyer, Sylvie
Eymard-Duvernay, Sabrina
Carrieri, Patrizia
Kouanfack, Charles
Domyeum, Jenny
Maradan, Gwenaëlle
Ducos, Jacques
Mpoudi-Ngolé, Eitel
Spire, Bruno
Delaporte, Eric
Kuaban, Christopher
Vidal, Laurent
Laurent, Christian
Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
title Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
title_full Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
title_fullStr Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
title_full_unstemmed Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
title_short Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
title_sort hepatitis b testing, treatment, and virologic suppression in hiv-infected patients in cameroon (anrs 12288 evolcam)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964089/
https://www.ncbi.nlm.nih.gov/pubmed/31941464
http://dx.doi.org/10.1186/s12879-020-4784-7
work_keys_str_mv AT liegeoisflorian hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT boyersylvie hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT eymardduvernaysabrina hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT carrieripatrizia hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT kouanfackcharles hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT domyeumjenny hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT maradangwenaelle hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT ducosjacques hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT mpoudingoleeitel hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT spirebruno hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT delaporteeric hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT kuabanchristopher hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT vidallaurent hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT laurentchristian hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam
AT hepatitisbtestingtreatmentandvirologicsuppressioninhivinfectedpatientsincameroonanrs12288evolcam